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Abstract
Teriparatide (TPTD) is the most widely used anabolic agent in the treatment of patients with osteoporosis although its use 
is restricted in many countries. A recent randomised trial confirmed that TPTD was superior to risedronate at preventing 
vertebral fractures over a 2-year period. There is limited information on the relative effectiveness of TPTD compared with 
standard care in routine clinical practice. In this paper, we report the results of an extended observational study of 724 women 
referred to a specialist clinic with severe osteoporosis over an 11.5-year period, who were considered for TPTD therapy. Of 
these patients, 496 (68.5%) were treated with TPTD, whereas the remaining 228 (31.5%) received other treatments. This 
was either because they were unwilling or unable to self-inject (52.6%), because they had already been established on oral 
bisphosphonates (31.1%) or because of contraindications (12.7%). The TPTD group were younger than the standard care 
group (69.6 vs. 74.1 years) and had a lower 10-year fracture risk (25.7% vs. 28.6%). Those treated with TPTD had a greater 
increase in BMD at the lumbar spine compared with standard care (13.3% vs. 8.2%, p < 0.001) after approximately 2 years 
and had a lower incidence of vertebral fractures (4.8% vs. 10.1%, p = 0.01) over the course of our observation. There was no 
difference between groups with respect to either BMD change at the femoral neck or incidence of non-vertebral fractures. 
This study confirms that TPTD is superior to standard care at reducing the risk of vertebral fracture in patients with severe 
osteoporosis.
Keywords Postmenopausal osteoporosis · Teriparatide · Observational study
Introduction
Teriparatide (TPTD) is an anabolic agent which has been 
shown to reduce the risk of both vertebral and non-vertebral 
fractures in postmenopausal women compared to placebo 
[1]. Teriparatide has also been shown to reduce the risk of 
vertebral fractures compared with oral alendronate in gluco-
corticoid induced osteoporosis and risedronate in postmeno-
pausal osteoporosis [2–5].
While randomised controlled trials (RCTs) are gener-
ally considered to be the gold standard for assessing the 
effects of new treatments [6], it is widely recognised that 
patients who take part in such trials are not representative 
of those being treated in routine clinical practice due to 
stringent inclusion and exclusion criteria. This was dem-
onstrated in a trial of 120 newly diagnosed osteoporotic 
female patients attending a referral centre in the USA, 
who were felt to be suitable candidates for therapy. How-
ever, only 3–21% of patients would have been eligible to 
take part in ongoing trials, mainly due to co-morbidity 
or concomitant medications [7]. Observational studies 
can therefore provide important information to comple-
ment the results of RCTs and their applicability to routine 
practice.
Our previous study, involving 323 patients followed up 
over a 5-year period, demonstrated TPTD was superior to 
standard care at reducing the risk of vertebral fractures in 
severe osteoporosis [8]. We have now extended this study 
to involve 724 patients followed up over an 11.5-year 
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period and have analysed changes in BMD and occurrence 
of fractures both during TPTD therapy and afterwards, 
following the introduction of antiresorptive therapy. The 
current study includes women from the initial study, but 
excludes 27 men. This reflects changes in prescribing from 
2008 onward necessitated by SMC guidance which did not 
recognise the use of TPTD in male osteoporosis.
Patients and Methods
Study Population
The study group comprised of 724 women who had been 
referred to a specialist clinic in NHS Lothian because of 
severe osteoporosis (defined as a T-score of equal or less 
than − 4.0 at the lumbar spine) between 2005 and 2016. 
The enrolment period was from February 2005 to July 
2016. Within this cohort, all patients were included in the 
fracture analysis and those with a duration of follow-up of 
more than 12 months were included in the BMD analysis 
(with the exception of one patient with a new diagnosis of 
coeliac disease who did not receive any specific treatment 
for osteoporosis).
The policy of the specialist clinic was to offer patients 
with a T score of − 4.0 or less TPTD therapy unless there 
was a contraindication, or they had already been stabilised 
on bisphosphonate therapy for 2 months or more.
Baseline Assessment
At the initial clinic visit, information was gathered as part 
of normal clinical care including; past medical history, 
previous and current medications, family history, alcohol 
intake, smoking status, and history of fractures. Blood 
tests were taken to measure urea and electrolytes, serum 
25(OH)D3 level, serum albumin and calcium. A 10-year 
fracture risk was calculated using the FRAX algorithm 
for each patient [9]. All patients underwent measurements 
of bone mineral density (BMD) at the lumbar spine, total 
hip and femoral neck using a Hologic QDR 4500 densi-
tometer. Lumbar spine values were based on the average 
of L1–L4 unless individual vertebra had been affected by 
fracture or other artefacts such as osteoarthritis (and if so, 
the average was based on evaluable vertebrae). The short 
term precision has been estimated at 1.3% for spine, 1.2% 
total hip and 1.4% for femoral neck, and long-term preci-
sion estimated at 2.4% for lumbar spine, 2.3% for total hip 
and 2.7% for femoral neck. The manufacturer (Hologic) 
supplied reference population based on over 50,000 DXA 
observations in the US population was used for calculat-
ing T scores.
Follow‑Up
Patients were typically reviewed at 4 months and 12 months 
after commencing treatment. At each review, they were asked 
about adherence to medications, fractures and adverse effects. 
Those who had received TPTD were transferred to an anti-
resorptive agent at the end of TPTD treatment (either 18 or 
24 months). Further reviews were performed 5 years after 
commencing therapy.
Measurements of bone mineral density (BMD) at the lum-
bar spine, total hip and femoral neck were repeated on the 
same machine after about 12 months and 24 months with the 
exception of patients who underwent an 18-month course 
of therapy in which case the scans were performed at 9 and 
18 months. Additional scans were performed at about 5 years 
after commencing therapy. Bone turnover markers were not 
performed routinely in this service.
Patients were asked about their fracture history at each 
clinic review. All fractures were confirmed by x-ray or 
other imaging by radiologists who were independent of 
the care team. Each patient’s electronic record was also 
reviewed retrospectively to identify any fractures that were 
not mentioned at clinic review. All fractures were recorded, 
but the final analysis included only the most common non-
vertebral fractures specified by the US Food and Drug 
Administration (FDA) [10], or major fractures specified 
by the European Union Committee for Medicinal Prod-
ucts for Human Use (CHMP) [11]. Facial, metacarpal, fin-
ger and toe fractures have been excluded from analysis in 
this study.
Statistical Analysis
Statistical analysis was performed using Minitab version 15 
(Minitab, State College, PA). Differences between groups 
were assessed either by t test for continuous variables or by 
Chi square test for categorical variables. Propensity scores 
were generated in SPSS version 22 (IBMM, Armonk, NY) 
entering age, sex, height, weight, smoking status, current 
glucocorticoid use, alcohol (3 or more units/day), rheu-
matoid arthritis, secondary osteoporosis and femoral neck 
BMD as predictors of treatment allocation. Sensitivity anal-
yses were performed using regression modelling entering 
treatment allocation as a categorical variable and either age 
and BMI or propensity score as continuous variables. Analy-
sis was by intention to treat and patients were not excluded 
if they either died during treatment or stopped treatment 
prematurely.




The characteristics of the TPTD and standard care groups 
are illustrated in Table 1. The baseline T score at the lum-
bar spine was similar in both groups. However, those in 
the standard care group had a significantly lower base-
line T score at the femoral neck and hip, compared to the 
TPTD group. The proportions of patients with a previous 
fracture were similar in both groups. Whilst the majority 
of patients were treatment naïve, 12.5% of patients in the 
TPTD group had failed to respond to a previous treatment, 
compared to 6.6% in the standard care group (p = 0.01). 
This was defined as a fall in BMD of more than 4% and 
the occurrence of a fragility fracture, or the occurrence 
of more than one fragility fracture despite adherence to 
therapy.
Patients who were treated with TPTD were significantly 
younger than those treated with standard care (69.6 years 
vs. 74.1 years, p < 0.001). A higher proportion of those in 
the standard care group had a history of cardiovascular dis-
ease (21.9% vs. 12.1%, p = 0.001) and previous malignancy 
(12.3% vs. 3.0%, p < 0.001). A total of 124 patients (17.1%) 
died during the study with death equally likely to occur in 
both groups. A higher proportion of the TPTD group had a 
history of parental hip fracture (18.4% vs. 11.4%, p = 0.02). 
The 10-year fracture risk, as determined by FRAX, was 
significantly higher in the standard care group than TPTD 
group (28.6% vs. 25.7%, p < 0.001). There was no signifi-
cant difference between groups in terms of body mass index, 
serum creatinine, serum 25(OH)D3, previous treatments, 
smoking status, alcohol intake and glucocorticoid use.
Treatments Received
The treatments received in the teriparatide and standard 
care groups are shown in Table 2. Teriparatide was pre-
scribed at a dose of 20 µg daily by patient administered 
subcutaneous injection. Between 2005 and June 2008, the 
treatment duration was 18 months and thereafter treat-
ment duration was 24 months due to changes in the UK 
product licence. Following completion of TPTD therapy, 
patients were offered anti-resorptive therapy according to 
usual standard clinical practice (see Table 2). Patients in 
the standard care group received a variety of therapies as 
shown in Table 1. Both groups of patients were also rou-
tinely co-prescribed calcium and vitamin D supplements 
at doses of 1,000 mg calcium and 800U vitamin D daily.
The reasons for not receiving TPTD in the standard 
care group were patient declined (n = 84, 36.8%), already 
stabilised on another treatment (n = 71, 31.1%), unwill-
ing or unable to self-inject (n = 36, 15.8%), unknown 
reason (n = 8, 3.5%) or contraindication (n = 29, 12.7%). 
The contraindications included impaired renal function 
(n = 6), previous malignancy (n = 7), previous radiotherapy 
(n = 11) or hyperparathyroidism (n = 5).
Follow‑on Therapy
The follow-on therapy for patients treated with teriparatide 
is illustrated in Table 3 (n = 395). No follow-up therapy 
information was available for patients who died whilst on 
TPTD treatment (n = 7, 1.4%), or who had not completed 
their course of TPTD (n = 94, 19.0%).
Response of BMD
The follow-up data for the response of BMD in both groups 
is displayed in Table 4. There was a significantly greater 
increase in the spine BMD in the TPTD group compared 
with the standard care group (7.2%/year vs. 4.4%/year, 
p = 0.00). There was no significant difference between 
groups in the BMD response at the femoral neck. There was 
a similar interval between scans in both groups (23.0 months 
vs. 22.3 months, p = 0.30). Sensitivity analyses were per-
formed to examine the role of potential confounders in 
view of the observational nature of this study. Teriparatide 
remained a highly significant predictor of improved BMD 
even after adjustment for age and body mass index, as well 
as after adjustment for treatment allocation propensity 
scores.
Bone mineral density changes at the spine and femo-
ral neck were analysed at different time intervals follow-
ing the initiation of treatment, as displayed in Fig. 1. In 
both groups, the greatest BMD increases were noted in 
the spine occurring within the first 12 months of treat-
ment. In the TPTD group, spine BMD increased by 
10.46% in the first year of treatment (n = 223), com-
pared with a 5.27% increase in the standard care group 
(n = 59). After a further year of TPTD the cumulative 
gain in spine BMD had reached 12.99% (n = 223), com-
pared to 8.60% in the standard care group (n = 48). Mod-
est increases in bone mineral density at the femoral neck 
were observed with no significant differences between 
the TPTD and standard care groups. In the TPTD group, 
femoral neck BMD increased by 1.39% in the first year 
of treatment (n = 224), compared with a 1.86% increase 
in the standard care group (n = 58). After a further year 
of TPTD the cumulative gain in femoral neck BMD had 
reached 3.1% (n = 223), compared to 3.7% in the stand-
ard care group (n = 49). Follow-up data after 5 years is 
available in a small number of the participants with the 
absolute changes in BMD appearing broadly similar to 
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those achieved at 2 years. Perhaps due to reduced num-
bers of participants and variation in treatment responses 
these differences did not reach statistical significance at 
either site (spine BMD gain of 12.8% with TPTD (n = 48) 
compared to 8.15% with standard care (n = 23), femoral 
neck BMD gain of 1.1% with TPTD (n = 49) compared to 
0.24% with standard care (n = 26).
Table 1  Characteristics of 
the teriparatide (TPTD) and 
standard care groups
p values refers to difference between groups by t test or Chi square test
a Defined as two or more
b Other previous treatments included TPTD: Strontium 7, Calcitonin 1, Raloxifene 6, Hormonal replace-
ment therapy (HRT) 16. Standard Care: Strontium 1, Raloxifene 1, H 1
c Bisphosphonates includes TPTD: Alendronate 113, Risedronate 35, Zoledronate 3, Ibandronate 3. Stand-
ard Care: Alendronate 70, Risedronate 16, Zoledronate 1, Ibandronate 1. All co-prescribed with calcium 
and vitamin D supplements
d Prescribed in the absence of any other osteoporosis medication
e Severe osteoporosis defined by bone mineral density T score of − 4 or less at the spine or hip
f Failure to respond to therapy defined as the occurrence of more than one fracture despite therapy adher-
ence or a decline in BMD and at least one fracture despite therapy adherence
TPTD (n = 496) Standard care (n = 228) p value
Demographics
 Age (Years) 69.6 ± 9.9 74.1 ± 9.1 <0.001
Baseline investigations
 Lumbar spine T score − 4.3 ± 0.7 − 4.4 ± 0.6 0.08
 Femoral neck T score − 3.0 ± 0.8 − 3.2 ± 0.8 <0.001
 Hip T score − 2.7 ± 0.9 − 3.1 ± 0.90 <0.001
 Body mass index (kg/m2) 23.3 ± 4.2 22.9 ± 4.1 0.16
 Serum creatinine (µM/L) 66.4 ± 14.2 69.7 ± 22.2 0.04
 Serum 25 (OH)D3 (nM/L) 57.2 ± 35.8 57.0 ± 33.3 0.90
Previous fractures
 Any fracture 421 (84.9%) 198 (86.8%) 0.48
 Vertebral fracture 273 (55.0%) 117 (51.3%) 0.35
 Multiple vertebral  fracturesa 171 (34.5%) 78 (34.2%) 0.94
Previous  treatmentsb
 No treatment 285 (57.4%) 120 (52.6%) 0.23
 Bisphosphonatesc 155 (31.2%) 86 (37.7%) 0.09
 Calcium/vitamin  Dd 163 (32.8%) 91 (39.9%) 0.07
Indication for treatment
 Postmenopausal osteoporosis 458 (92.3%) 212 (93.0%) 0.76
 Severe  osteoporosise 405 (81.6%) 189 (82.9%) 0.69
 Resistant to  therapiesf 62 (12.5%) 15 (6.6%) 0.01
Morbidities
 Chronic obstructive pulmonary disease 81 (16.3%) 40 (17.5%) 0.68
 Cardiovascular disease 60 (12.1%) 50 (21.9%) 0.001
 Diabetes mellitus 15 (3.0%) 9 (3.9%) 0.52
 Malignancy 15 (3.0%) 28 (12.3%) <0.001
 Death 84 (16.9%) 40 (17.5%) 0.5
Other factors
 Smoker 99 (19.9%) 44 (19.3%) 0.85
 Alcohol (units/week) 3.2 ± 5.7 2.5 ± 7.4 0.25
 Glucocorticoid use 34 (6.9%) 18 (7.9%) 0.62
 Rheumatoid arthritis 35 (7.1%) 19 (8.3%) 0.55
 Parental hip fracture 91 (18.4%) 26 (11.4%) 0.02
 10-year fracture risk % (FRAX) 25.7 ± 11.6 28.6 ± 12.8 <0.001
10-year hip fracture risk % (FRAX) 12.5 ± 10.5 15.9 ± 12.9 <0.001
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Fractures
In the TPTD group, the proportion of patients with ver-
tebral fractures was fewer than in the standard care group 
(4.8% vs. 10.1%, p = 0.01), as illustrated in Table 5. This 
difference remained statistically significant after adjusting 
for baseline FRAX score, and for treatment allocation 
propensity scores. The duration of follow-up was simi-
lar in both groups (53.8 vs. 54.4 months, p = 0.86). The 
difference in multiple vertebral fractures (1.8% vs 3.9%, 
p = 0.09) was not statistically significant.
There was no difference between groups in terms of 
non-vertebral fracture. In the TPTD group, a total of 133 
non-vertebral fractures were sustained, in 105 individuals 
(21.2%). The majority of these were at the hip (n = 30, 
6.1%) and wrist (n = 31, 6.3%). Others included humerus 
(n = 14, 2.8%), rib/clavicle (n = 8, 1.6%), ankle (n = 10, 
2.0%), pelvis (n = 13, 2.6%) and other sites (n = 27, 5.4%). 
Six fractures were excluded from analysis. In the standard 
care group, a total of 55 non-vertebral fractures occurred 
in 49 women (21.5%). The majority of these were at the 
hip (n = 15, 6.6%), wrist (n = 10, 4.4%) or pelvis (n = 11, 
4.8%). Other fractures included humerus (n = 4, 1.8%), 
ribs/clavicle (n = 7, 3.1%), ankle (n = 4, 1.8%) or other 
sites (n = 4, 1.8%). Four fractures were excluded from 
analysis.
Discussion
Teriparatide is approved for the restricted treatment of severe 
osteoporosis in postmenopausal women. The anabolic mech-
anism of action is distinctly different from the anti-resorptive 
effects of bisphosphonates, which are the mainstay of treat-
ment for osteoporosis. In the United Kingdom, the use of 
TPTD is restricted to certain patient groups due to guidance 
from regulatory bodies including the National Institute of 
Clinical Excellence (NICE) [12], the Scottish Medicines 
Consortium (SMC) [13], and the Scottish Intercollegiate 
Guidelines Network (SIGN) [14]. Current NICE guidelines 
suggest TPTD is recommended as an alternative treatment 
option in postmenopausal women for secondary prevention 
of osteoporotic fractures under the following conditions: 
patients must be aged 65 or over with a T score of − 4.0 
or less (or a T score of − 3.5 or less with more than two 
previous fractures, or aged 55–64 with a T score of − 4.0 
or less plus more than two previous fractures) and unable 
to take oral bisphosphonates or strontium ranelate (due to 
contra-indications or intolerance) or have an unsatisfactory 
response to oral bisphosphonate [12]. The Scottish Medi-
cine Consortium (SMC) guidance suggests TPTD therapy is 
acceptable for use in severe osteoporosis for postmenopausal 
women, under specialist use. In 2008, the SMC stated it did 
not recommend TPTD for the treatment of osteoporosis in 
men [13]. Based on SMC advice and the SIGN guidance, 
TPTD is predominantly used by specialists in Scotland for 
the treatment of severe osteoporosis in postmenopausal 
women.
Table 2  Treatment regimens in teriparatide and standard care group
Details of treatment regimens; Alendronate (oral 70  mg once 
weekly), Zoledronic acid (intravenous 5  mg annually), Risedronate 
(oral 35  mg once weekly), Denosumab (subcutaneous 60  mg 6 
monthly), Strontium ranelate (oral 2 g once daily). In accordance with 
standard practice in the UK, oral bisphosphonates were prescribed for 
5 years, at which stage a repeat bone density scan was performed. If 
at this point BMD values were in the osteoporotic range, then treat-
ment was continued for 10 years. Intravenous zoledronate was given 
as 3 annual infusions followed by a 3-year drug holiday. Denosumab 
was offered for 5 years in the first instance
a Note all of the above were co-prescribed calcium and vitamin D, 
once daily
b Other treatments include denosumab (n = 8, 3.5%), calcium/vitamin 
D alone (n = 4, 1.7%), Strontium ranelate (n = 2, 0.8%), unknown 
(n = 8, 3.5%)
Teriparatide (n = 496) Standard care (n = 228)





96 (19.4%) Alendronatea 159 (69.1%)





400 (80.6%) Risedronatea 17 (7.4%)
Other  treatmentsb 22 (9.6%)
Table 3  Follow-on therapy after course of Teriparatide treatment 
(n = 395)
Details of treatment regimens: Alendronate (oral 70  mg once 
weekly), Zoledronic acid (intravenous 5  mg annually), Risedronate 
(oral 35  mg once weekly), Denosumab (subcutaneous 60  mg six 
monthly), Strontium ranelate (oral 2 g once daily)
a Co-prescribed Calcium (1000 mg) and Vitamin D (800 units) daily
b Other treatment includes; Denosumab (n = 27, 5.5%), Calcium/vita-
min D alone (n = 5, 1.0%), Strontium ranelate (n = 1, 0.2%), Hormo-
nal replacement therapy (n = 1, 0.2%), further course of TPTD (n = 1, 
n = 0.2%)
Follow-on therapy after Teriparatide Number of patient (%)
Alendronatea 213 (53.9%)
Risedronatea 18 (4.5%)
Zoledronic  Acida 117 (29.6%)
Other  treatmentb 35 (8.9%)
No treatment 9 (2.3%)
Not known 3 (0.8%)
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Teriparatide has demonstrated effectiveness in ran-
domised clinical trials in terms of improving bone mineral 
density and reducing fracture incidence compared to pla-
cebo [1]. Comparative studies with bisphosphonates have 
also illustrated a superior effect of TPTD in improving bone 
mineral density and reducing the risk of vertebral fractures 
in postmenopausal osteoporosis and glucocorticoid-induced 
osteoporosis (noting that Body et al. used a higher daily 
dose of teriparatide) [2–4, 15]. The VERO study compared 
TPTD with risedronate in a population of 1360 women using 
incidence fractures as the primary outcome. The study indi-
cated that the fracture risk in patients receiving TPTD was 
significantly lower than that of the patients receiving rise-
dronate [5]. A recent meta-analysis of six randomised tri-
als comparing TPTD to alendronate reiterated that TPTD 
therapy is associated with a greater increase in lumbar spine 
BMD [16].
There exist little data describing the effectiveness of 
TPTD out with a randomised controlled trial setting. We 
previously reported an observational study, in which we 
reviewed the clinical outcome for patients with severe 
osteoporosis treated with either TPTD or standard care over 
around 5 years. We identified that in a total population of 
323 patients, TPTD was superior in preventing new vertebral 
fractures and improving spine BMD, compared to standard 
care, in routine clinical practice [8].
Here, we have extended this study considerably. Not 
only was the sample size greater, but we also analysed the 
long-term response following introduction of antiresorptive 
therapy. The present study showed that patients treated with 
TPTD had a significantly greater increase in BMD at the 
spine, compared with standard care. There was no significant 
difference between groups in terms of the change in femoral 
neck BMD or total hip BMD. These findings are in keep-
ing with previous randomised controlled trials comparing 
TPTD and bisphosphonates [2–5] and are also similar to our 
previous study in which we observed an 8.2%/year increase 
in spine BMD with TPTD and a 5.0%/year increase with 
standard care [8] compared with 7.2%/year in the TPTD 
group and 4.4%/year in the standard care group in the pre-
sent study.
Those treated with TPTD therapy had a lower inci-
dence of vertebral fractures compared to those treated 
with standard care (4.8% vs, 10.1%, p = 0.01), but there 
was no significant difference in the incidence of non-ver-
tebral fractures. This is, again, in keeping with our previ-
ous findings [8]. We observed a slightly higher vertebral 
fracture incidence in both groups in this analysis, which is 
likely due to the longer follow-up period (53–54 months). 
Randomised comparative trials have also shown superi-
ority of TPTD over bisphosphonates in preventing ver-
tebral fractures but yielding no significant difference in 
non-vertebral fractures. For example, in the VERO trial 
of 1360 women treated with either TPTD or risedronate, 
vertebral fracture rate was 5.4% in the TPTD group and 
12% in the risedronate group (p = <0.0001), whereas the 
incidence of non-vertebral fragility fractures was 4.0% vs 
6.1% (p = 0.10) [5].
We also analysed the effect on bone mineral density fol-
lowing cessation of TPTD by which point most patients 
had received anti-resorptive therapy with bisphosphonates. 
As expected, the greatest gain in BMD occurred in the first 
12 months of treatment, with gains over the first 2 years also 
significantly higher in the TPTD treated group. Although 
the absolute change in bone density remained very similar 
in those patients followed up for 5 years, the difference was 
no longer significant presumably due to greater variation 
in BMD seen and the much smaller number of patients in 
whom this data was available.
The study has several limitations. It was an observa-
tional study and therefore allocation to treatments was not 
randomised. As a reflection of this fact, patients treated 
with standard care were older, had a higher femoral neck 
T-score, had a history of malignancy and had lower serum 
creatinine levels than those receiving TPTD. This indi-
cates that in routine practice, older, more frail individuals 
Table 4  Bone Mineral Density (BMD) changes in the study population
Based on longest scan interval performed between months 12 and 36 after baseline visit. Values are mean ± standard deviation, unadjusted p 
values refer to difference between groups by t test, adjusted p values refer to significance attributable to teriparatide as a categorical predictor of 
outcome in regression models incorporating age and BMI or propensity scores, respectively





Scan Time (Months) 23.0 ± 5.1 22.3 ± 6.4 0.30 0.50 0.61
Change in lumbar spine BMD (%) 13.3 ± 8.8 8.2 ± 8.7 0.00 0.00 0.00
Change in femoral neck BMD (%) 3.0 ± 9.9 3.3 ± 7.1 0.78 0.70 0.67
Change in lumbar spine BMD (%/year) 7.2 ± 5.2 4.4 ± 4.9 0.00 0.00 0.00
Change in femoral neck BMD (%/year) 1.5 ± 5.1 2.0 ± 4.0 0.50 0.43 0.45
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might elect not to have TPTD therapy. It is also not possi-
ble to accurately assess patient compliance in either group 
and therefore we are unable to exclude the possibility that 
the favourable result with TPTD may be related to compli-
ance. In terms of monitoring bone mineral density, we did 
not have repeat scans for all patients at the desired time 
interval, resulting in a reduced study power. Finally, we 
did not systematically gather information on side effects; 
however, we can report that there were no major adverse 
events of symptomatic hypercalcaemia, osteonecrosis of 
the jaw or atypical femoral fractures in either treatment 
group.
However, the strength of this study is that it provides 
information regarding the use of TPTD and other osteo-
porosis therapies in daily clinical practice. This data is 
unique as it includes elderly patients with multiple co-
morbidities, of whom a few are likely to meet the criteria 
to be included in controlled trials. It therefore assists with 
the interpretation of how findings from randomised con-
trolled trials may translate into routine clinical practice. 
The longer duration of follow-up and larger study popula-
tion allow us to more confidently interpret these results. 
It is promising that many of the findings described in the 
randomised controlled trial setting still translate to daily 
clinical care, notably the beneficial effects on spine BMD 
and vertebral fracture incidence. This may add reassur-
ance to clinicians who are selecting appropriate patients 
to commence anabolic therapy for severe osteoporosis in 
daily clinical practice.
In summary, teriparatide is an anabolic agent used in the 
treatment of severe osteoporosis under restricted following 
guidance from regulatory authorities. It has demonstrated 
superiority in improving BMD and reducing fracture risk in 
multiple patient populations in randomised controlled trials. 
Here, we report upon observational data recorded over an 
11.5-year period in 724 women comparing the outcomes in 
those treated with TPTD versus those treated with standard 
care. Those treated with TPTD in routine clinical practice 
have an improved spinal BMD and a reduced incidence of 
vertebral fractures. Our study therefore suggests that TPTD 
may be preferable to standard therapy in women with severe 
spinal osteoporosis.
Fig. 1  Gains in Bone Mineral Density (BMD) shown in the Spine 
(panel A) or in the Total Hip and Femoral Neck (panel B) meas-
ured over the course of the study. Values are mean ± standard error. 
* indicates p values less than 0.01 referring to difference between 
groups by t test. Change in BMD refers to total change in BMD from 
baseline scan at study entry to repeat scan date. There was no sig-
nificant difference in the scan interval between groups. Within the 
Teriparatide (TPTD) cohort, BMD information was available in 224 
women (year 1), 227 women (year 2) and 49 women (year 5). Within 
the standard care (SC) group, BMD information was available in 59 
women (year 1), 49 women (year 2) and 26 women (year5)
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Table 5  Fracture incidence in the study population
Values are numbers (percentage), unadjusted p values refer to difference in groups by Chi square test, adjusted p values refer to significance 
attributable to teriparatide as a categorical predictor of outcome in regression models incorporating FRAX total fracture score or FRAX hip frac-
ture score, or propensity scores, respectively
a Defined as two or more









Duration of follow-up (months) 53.8 54.4 0.86 0.97 0.97 0.98
Vertebral fractures 24 (4.8%) 23 (10.1%) 0.01 0.01 0.01 0.03
Non vertebral fractures 105 (21.2%) 49 (21.5%) 0.92 0.81 0.64 0.53
Multiple vertebral  fracturesa 9 (1.8%) 9 (3.9%) 0.09 0.12 0.13 0.35
Multiple non vertebral  fracturesa 23 (4.7%) 6 (2.6%) 0.19 0.11 0.10 0.06
